The 12 analysts offering 1 year price forecasts for MLTX have a max estimate of — and a min estimate of —.
Analyst rating
Based on 14 analysts giving stock ratings to MLTX in the past 3 months.
EPS
0.00
Reported
Estimate
Reported
Estimate
Surprise
Revenue
0.00
Reported
Estimate
Reported
Estimate
Surprise
Be warned
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
Frequently Asked Questions
MLTX EPS for the last quarter is −0.56 USD despite the estimation of −0.44 USD. In the next quarter EPS is expected to reach −0.60 USD. Track more of MoonLake Immunotherapeutics financials and stay on top of what is up with the company.
According to analysts, MLTX price target is 74.08 USD with a max estimate of 104.00 USD and a min estimate of 55.00 USD. Check if this forecast comes true in a year, meanwhile watch MoonLake Immunotherapeutics stock price chart and keep track of the current situation with MLTX news and stock market news.
We've gathered opinions of 14 analysts rating MLTX stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as strong buy. Note that it's not a trading advice — your own analysis is still required.